 |
Plan and prepare now, minimize
negative impact later
Pandemic flu planning by organizations and businesses is a self service and a public service: plans put into place now will play a key role in protecting employees' health and safety as well as limiting the negative impact to organizations, the economy and society.[20]
The time for planning is now and the need for planning is urgent, according to a 2006 report from the Department of Health and Human Services on pandemic flu planning. The plan encouraged Americans to “pick up the pace” and “renew pandemic preparations on every front.”[21]
In order to help you process these stirring words into action, PandemicPlanGSK.com offers you a review of planning strategies and measures—nationally and for your organization.
next:
US government
preparations
Important Safety Information About RELENZA
RELENZA IS NOT RECOMMENDED FOR TREATMENT OR PROPHYLAXIS OF INFLUENZA IN INDIVIDUALS WITH UNDERLYING AIRWAY DISEASE (SUCH AS ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE).
- Serious cases of bronchospasm, including fatalities, have been reported during treatment with RELENZA in patients with and without underlying airway disease. Many of these cases were reported during postmarketing, and causality was difficult to assess
- RELENZA SHOULD BE DISCONTINUED IN ANY PATIENT WHO DEVELOPS BRONCHOSPASM OR DECLINE IN RESPIRATORY FUNCTION; immediate treatment and hospitalization may be required
- Safety and efficacy have not been demonstrated in patients with high-risk underlying medical conditions
- Patients should be instructed in the use of the delivery system. Instructions should include a demonstration whenever possible
- If treatment with RELENZA is considered for a patient with underlying airway disease, the potential risks and benefits should be carefully weighed. If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care including availability of fast-acting bronchodilators
- Common adverse events in treatment and prophylaxis studies with RELENZA were nausea, diarrhea, sinusitis, viral respiratory infections, headaches, nasal signs and symptoms. The incidence of these adverse events was similar in both groups for RELENZA and placebo-treated groups
- Please see complete Prescribing Information for RELENZA
|
|
view PDF
“Pick up the pace”
– Commentary on public/private pandemic flu planning (Department of Health and Human Services, 2006)
|
